Illumina TruSight Tumor OncoPanel

Illumina has launched TruSight Tumor 15, a next-generation sequencing panel designed to identify sequencing variants in 15 genes commonly associated with marketed therapeutics. TruSight Tumor 15 is optimized for degraded formalin-fixed, paraffin embedded tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs. When paired with the Illumina MiSeq system, the panel delivers high-quality sequencing with key content and features needed for tumor analysis in translational research, Illumina said.